FDA CRL Delays ViiV’s Long-Acting Cabotegravir Regimen

Manufacturing Questions Triggered FDA Complete Response Letter

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.